Skip to main content

Table 3 Patients' characteristics according to ICIs initiation within 3 months of death

From: PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

 

Control

ICIs started within 3 months of death

 

N° (%)

N° (%)

444 (78.3)

123 (21.7)

Age

   

 < 60 years old

124 (27.9)

24 (19.5)

P = 0.0603

P = 0.8261

 ≥ 60 years old

320 (72.1)

99 (80.5)

 < 70 years old

254 (57.2)

69 (56.1)

 ≥ 70 years old

190 (42.8)

54 (43.9)

Gender

  

P = 0.3171

 Female

155 (34.9)

37 (30.1)

 Male

289 (65.1)

86 (69.9)

ECOG PS

  

P < 0.0001

 0—1

387 (87.2)

87 (70.7)

  ≥ 2

57 (12.8)

36 (29.3)

Primary tumor

  

P = 0.0236

 NSCLC

261 (58.8)

91 (74.0)

 Melanoma

94 (21.2)

17 (13.8)

 Renal cell carcinoma

71 (16.0)

12 (9.8)

 Others

18 (4.1)

3 (2.4)

No. of metastatic sites

  

P = 0.0025

 ≤ 2

182 (41.0)

32 (26.0)

  > 2

262 (59.0)

91 (74.0)

Treatment line

  

P = 0.0189

 First

138 (31.1)

35 (28.5)

 Second

243 (54.7)

81 (65.9)

 Further lines

63 (14.2)

7 (5.7)

  1. ICI: immune checkpoint inhibitor; ECOG-PS: eastern cooperative oncology group-performance status; NSCLC: non-small cell lung cancer